Cargando…

Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis

Supplemental Digital Content is available in the text

Detalles Bibliográficos
Autores principales:	Sousos, Nikolaos, Buck, Gemma, Rodriguez-Meira, Alba, Norfo, Ruggiero, Hamblin, Angela, Pezzella, Francesco, Davies, Jennifer, Hublitz, Philip, Psaila, Bethan, Mead, Adam J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306308/ https://www.ncbi.nlm.nih.gov/pubmed/32647791 http://dx.doi.org/10.1097/HS9.0000000000000356

Ejemplares similares

In utero origin of myelofibrosis presenting in adult monozygotic twins
por: Sousos, Nikolaos, et al.
Publicado: (2022)

Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing
por: Rodriguez-Meira, Alba, et al.
Publicado: (2019)

Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia
por: Louka, Eleni, et al.
Publicado: (2021)

Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets
por: Psaila, Bethan, et al.
Publicado: (2020)

Correction Notice: Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis
Publicado: (2021)

Chronic Lymphocytic Leukemia and Myelofibrosis
por: Darawshy, Fares, et al.
Publicado: (2018)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution
por: Rodriguez-Meira, Alba, et al.
Publicado: (2023)

Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm Biology
por: Royston, Daniel, et al.
Publicado: (2021)

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
Publicado: (2013)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

Myelofibrosis in 2019: moving beyond JAK2 inhibition
por: Schieber, Michael, et al.
Publicado: (2019)

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2013)

Will JAK1/2 inhibitors change the standard of care for myelofibrosis?
por: Jung, Chul Won
Publicado: (2012)

Cutaneous cryptococcosis in a patient with myelofibrosis receiving JAK‐inhibitor
por: Chen, Jui‐Che, et al.
Publicado: (2021)

Impaired antibody response to COVID‐19 vaccination in patients with chronic myeloid neoplasms
por: Chowdhury, Onima, et al.
Publicado: (2021)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
por: Tvorogov, Denis, et al.
Publicado: (2018)

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
por: Kuykendall, Andrew T., et al.
Publicado: (2020)

Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis
por: Brown, Derek W., et al.
Publicado: (2022)

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
por: Mascarenhas, John O., et al.
Publicado: (2022)

Transitions in lineage specification and gene regulatory networks in hematopoietic stem/progenitor cells over human development
por: Roy, Anindita, et al.
Publicado: (2021)

Is it primary myelofibrosis or chronic megakaryocytic leukemia?
por: Lichtman, Marshall A.
Publicado: (2022)

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis
por: Brattås, Marte Karen, et al.
Publicado: (2018)

The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis
por: Barone, Martina, et al.
Publicado: (2020)

Development of JAK2 positive myelofibrosis on a background of chronic myeloid leukaemia
por: Mullen, Christopher Gerard, et al.
Publicado: (2022)

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
por: Tremblay, Douglas, et al.
Publicado: (2023)

Correction: Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients
por: Ryou, Hosuk, et al.
Publicado: (2023)

Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients
por: Ryou, Hosuk, et al.
Publicado: (2022)

Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
por: Angotzi, Francesco, et al.
Publicado: (2022)

miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6
por: Rontauroli, Sebastiano, et al.
Publicado: (2017)

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: dos Santos, Leonardo Caires, et al.
Publicado: (2011)

Many questions raised by a question on JAK1/2 inhibitors in primary myelofibrosis
por: Raut, Lalit
Publicado: (2013)

Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era
por: Del Sordo, Rachele, et al.
Publicado: (2017)

A tale of two alleles: TP53 and transformation in MPNs
por: Brierley, Charlotte, et al.
Publicado: (2022)

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
por: Tefferi, Ayalew, et al.
Publicado: (2023)

Processing single-cell RNA-seq datasets using SingCellaR
por: Wang, Guanlin, et al.
Publicado: (2022)

Coexisting BRAF-Mutated Langerhans Cell Histiocytosis and Primary Myelofibrosis with Shared JAK2 Mutation
por: Holst, Johanne Marie, et al.
Publicado: (2021)

Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib
por: Yi, Jun Ho, et al.
Publicado: (2019)

Acute myelofibrosis superseding B‐lymphoblastic leukemia/lymphoma
por: El Hussein, Siba, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d4u6u2qi3n6h1ndrdohvi8c8d1